Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Teddy Rosenbluth
Author: Teddy Rosenbluth

Written by

Teddy Rosenbluth

in

Cassava Sciences Inc, Clinical Trials, Decisions and Verdicts, Falsification of Data, Regulation and Deregulation of Industry, Research, Securities and Commodities Violations, simufilam
←At the Brooklyn Academy, Musical Journeys Through Minefields
EV Projects to Get $13 Billion in Federal Loans→

More posts

  • U.S. military strikes Iran, while Trump vows more for Tehran’s retaliation

  • Have title challengers done enough in transfer window to challenge Arsenal?

  • South Korea jails disabled care home head for sexually assaulting residents

  • New York City Public Schools banning AI use through middle school this year

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube